IIM
CRSP icon

INTECH Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

INTECH Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.24M Sell
22,697
-2,302
-9% -$121K 0.01% 931
2026
Q1 		$1.19M Sell
24,999
-3,045
-11% -$161K 0.01% 938
2025
Q4 		$1.47M Buy
28,044
+5,140
+22% +$308K 0.01% 907
2025
Q3 		$1.48M Sell
22,904
-16,079
-41% -$923K 0.01% 954
2025
Q2 		$1.9M Buy
+38,983
New +$1.51M 0.02% 796

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

INTECH Investment Management's CRSP Position: Q2 2026 in Review

INTECH Investment Management reduced its CRISPR Therapeutics (CRSP) stake by 9.2% in Q2 2026, selling an estimated $121K and leaving 22,697 shares worth $1.24M. The position accounts for 0.01% of the portfolio, ranked #931.

INTECH Investment Management first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.9M in Q2 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • INTECH Investment Management held 22,697 shares of CRISPR Therapeutics worth $1.24M as of Q2 2026.
  • INTECH Investment Management sold 2,302 CRISPR Therapeutics shares in Q2 2026, an estimated $121K.
  • CRISPR Therapeutics made up 0.01% of INTECH Investment Management's portfolio in Q2 2026, its #931 holding.
  • INTECH Investment Management first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • INTECH Investment Management's CRISPR Therapeutics position peaked at $1.9M in Q2 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.